200 related articles for article (PubMed ID: 11555379)
1. Diagnostic utility of CYFRA 21-1 in malignant pleural effusion.
Dejsomritrutai W; Senawong S; Promkiamon B
Respirology; 2001 Sep; 6(3):213-6. PubMed ID: 11555379
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion.
Lai RS; Chen CC; Lee PC; Lu JY
Jpn J Clin Oncol; 1999 Sep; 29(9):421-4. PubMed ID: 10563194
[TBL] [Abstract][Full Text] [Related]
3. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions.
Romero S; Fernández C; Arriero JM; Espasa A; Candela A; Martín C; Sánchez-Payá J
Eur Respir J; 1996 Jan; 9(1):17-23. PubMed ID: 8834328
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions.
Ferrer J; Villarino MA; Encabo G; Felip E; Bermejo B; Vilà S; Orriols R
Cancer; 1999 Oct; 86(8):1488-95. PubMed ID: 10526277
[TBL] [Abstract][Full Text] [Related]
5. Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions.
Lee YC; Knox BS; Garrett JE
Aust N Z J Med; 1999 Dec; 29(6):765-9. PubMed ID: 10677119
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
[TBL] [Abstract][Full Text] [Related]
8. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions.
Korczynski P; Krenke R; Safianowska A; Gorska K; Abou Chaz MB; Maskey-Warzechowska M; Kondracka A; Nasilowski J; Chazan R
Eur J Med Res; 2009 Dec; 14 Suppl 4(Suppl 4):128-33. PubMed ID: 20156743
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of CTLA-4, carcinoembryonic antigen and CYFRA 21-1 for malignant pleural effusion.
Chen M; Xie S; Wan C; Zeng N; Wu Y; Qin J; Shen Y; Wen F
Postgrad Med; 2017 Aug; 129(6):644-648. PubMed ID: 28506100
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of tumor markers Cyfra 21-1 and neuron-specific enolase in analysis of pleural fluid.
Lyubimova NV; Yag'ya TN; Chuchalin AG; Kushlinskii NE
Bull Exp Biol Med; 2002 May; 133(5):478-80. PubMed ID: 12420066
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
Lee JH; Chang JH
Chest; 2005 Oct; 128(4):2298-303. PubMed ID: 16236887
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis.
Gu P; Huang G; Chen Y; Zhu C; Yuan J; Sheng S
J Clin Lab Anal; 2007; 21(6):398-405. PubMed ID: 18022924
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of CYFRA 21-1 and CEA assays in pericardial fluid for the recognition of neoplastic pericarditis.
Szturmowicz M; Tomkowski W; Fijalkowska A; Kupis W; Cieślik A; Demkow U; Langfort R; Wiechecka A; Orlowski T; Torbicki A
Int J Biol Markers; 2005; 20(1):43-9. PubMed ID: 15832772
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic value of the tumor markers TPA-M, CYPFRA 21-1 and CEA in pleural effusion. Prospective comparison of thoracoscopic investigations in patients with pleural effusion].
Riedel U; Schönfeld N; Savaser A; Serk M; Loddenkemper R
Pneumologie; 1999 Oct; 53(10):471-6. PubMed ID: 10596548
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions.
Salama G; Miédougé M; Rouzaud P; Mauduyt MA; Pujazon MC; Vincent C; Carles P; Serre G
Br J Cancer; 1998; 77(3):472-6. PubMed ID: 9472646
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of CYFRA 21-1 in malignant pleural fluids.
Satoh H; Sumi M; Yagyu H; Ishikawa H; Suyama T; Naitoh T; Saitoh T; Hasegawa S
Oncology; 1995; 52(3):211-4. PubMed ID: 7536317
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis.
Liang QL; Shi HZ; Qin XJ; Liang XD; Jiang J; Yang HB
Thorax; 2008 Jan; 63(1):35-41. PubMed ID: 17573438
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma.
Huang WW; Tsao SM; Lai CL; Su CC; Tseng CE
Pathology; 2010 Apr; 42(3):224-8. PubMed ID: 20350214
[TBL] [Abstract][Full Text] [Related]
20. Pleural CEA, CA-15-3, CYFRA 21-1, CA-19-9, CA-125 discriminating malignant from benign pleural effusions: Diagnostic cancer biomarkers.
Fazli Khalaf F; Asadi Gharabaghi M; Balibegloo M; Davari H; Afshar S; Jahanbin B
Int J Biol Markers; 2023 Jun; 38(2):81-88. PubMed ID: 36942429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
